Investigational drug · Phase 2
ARX788
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for HER2 Positive Metastatic Breast Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Mar 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
12
Any phase or sponsor naming "ARX788"
First trial start
2021
Oct 26, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ARX788", any sponsor or status.
- Phase 210
Conditions studied
As listed on its trial records.
- HER2 Positive Metastatic Breast Cancer
Approved drugs for the same conditions: Breast cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "ARX788" as an intervention, largest first.
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerPivotal-lookingRecruiting
QuantumLeap Healthcare CollaborativeAcademic, hospital or other
NCT01042379 · 5,000 participants (planned) · Start Mar 1, 2010 · Primary completion Dec 2030
Drug: Standard Therapy; AMG 386 with or without Trastuzumab and 44 more · For: Breast Neoplasms; Breast Cancer; Breast Tumors and 8 more
Sites: Birmingham, Alabama; Scottsdale, Arizona; Tucson, Arizona · 42 sites in all
- A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer PatientsPivotal-lookingActive, not recruiting
Caigang LiuAcademic, hospital or other
NCT05426486 · 136 participants (planned) · Start May 23, 2022 · Primary completion Dec 30, 2025
Drug: ARX788; Pyrotinib maleate and 4 more · For: HER2-positive Breast Cancer
Sites: Shenyang, China
Ambrx, Inc.Industry
NCT03255070 · 106 participants · Start Mar 20, 2018 · Primary completion Sep 13, 2023
Drug: ARX788 · For: Breast Neoplasms; Gastric Neoplasm; Solid Tumors
Sites: Los Angeles, California; Santa Monica, California; St Louis, Missouri · 12 sites in all
- ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)Active, not recruiting
Ambrx, Inc.Industry
NCT04829604 · 72 participants · Start Oct 26, 2021 · Primary completion Dec 2026
Drug: ARX788 · For: HER2 Positive Metastatic Breast Cancer
Sites: Los Angeles, California; Newport Beach, California; San Francisco, California · 33 sites in all
- ARX788 in Breast Cancer With Low Expression of HER2Status unknown
Fudan UniversityAcademic, hospital or other
NCT05018676 · 54 participants (planned) · Start Oct 20, 2021 · Primary completion Dec 30, 2022
Drug: ARX788 · For: Breast Cancer With Low Expression of HER2
Sites: Shanghai, China
Henan Cancer HospitalGovernment (non-federal)
NCT06663748 · 44 participants (planned) · Start Jun 16, 2025 · Primary completion Nov 20, 2027
Drug: ARX788 · For: HER2-positive, Metastatic Breast Cancer
Sites: Zhengzhou, China
- ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXdNot yet recruiting
Fudan UniversityAcademic, hospital or other
NCT06578286 · 44 participants (planned) · Start Sep 30, 2024 · Primary completion Sep 30, 2026
Drug: ARX788 · For: Breast Cancer
- ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast CancerRecruiting
Laura Huppert, MD, BAAcademic, hospital or other
NCT06224673 · 36 participants (planned) · Start Jun 5, 2026 · Primary completion Nov 30, 2029
Drug: ARX788; Amiloride · For: HER2 Low Breast Carcinoma; Triple Negative Breast Cancer; Hormone-receptor-positive Breast Cancer and 1 more
Sites: San Francisco, California
Fudan UniversityAcademic, hospital or other
NCT05018702 · 32 participants (planned) · Start Jul 14, 2021 · Primary completion Dec 30, 2022
Drug: ARX788 · For: HER2-positive, Metastatic Breast Cancer
Sites: Shanghai, China
Shengjing HospitalAcademic, hospital or other
NCT04983121 · 30 participants (planned) · Start Aug 1, 2021 · Primary completion Aug 15, 2027
Drug: Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788) · For: Breast Neoplasms
Sites: Shenyang, China
Newest research
PubMed records naming it or its code names, newest first.
- Efficacy and safety of antibody-drug conjugates in pretreated HER2-positive advanced breast cancer: a network meta-analysis of randomized controlled trials.
Liu F, Pan Y, Li J, et al. · Front Pharmacol 2026
- Resistance mechanisms and post-trastuzumab deruxtecan (T-DXd) strategies in HER2+ and HER2-low breast cancer: From biology to clinical practice.
Wen X, Wang W, Song J, et al. · Crit Rev Oncol Hematol 2026
- Treatment-Related Toxicities of Antibody-Drug Conjugates in Breast Cancer: A Bayesian Network Meta-Analysis.
Han Y, Xu H, Yao Y, et al. · Cancer Control 2026
- Efficacy and safety of ARX788 for individuals with HER2-positive breast cancer and brain metastases (ACE-Breast-06): a single-arm, phase 2 trial in China.
Li T, Lin M, Wang B, et al. · EClinicalMedicine 2025
- Bystander effect in antibody-drug conjugates: Navigating the fine line in tumor heterogeneity.
Wang Y, Cheng X, Li X, et al. · Crit Rev Oncol Hematol 2025
- Neoadjuvant ARX788 plus pyrotinib versus trastuzumab, pertuzumab, docetaxel and carboplatin for HER2-positive breast cancer: a randomised phase 2b trial.
Niu N, Xue J, Chen G, et al. · Nat Commun 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.